CVS Health reported 402.1 billion dollars of total revenue in 2025, a company record. As a qualification signal that number is close to worthless, because almost none of it is spent by the same people. CVS Health reports three operating segments, and they are three genuinely different businesses sharing a logo:
| Segment | 2025 revenue | What it actually is |
|---|---|---|
| Health Services | 190.4 billion dollars | The Caremark pharmacy benefit manager, specialty and mail pharmacy, and care delivery. It processed 1.9 billion pharmacy claims in 2025. |
| Health Care Benefits | 143.4 billion dollars | Aetna. A regulated insurer with 26.6 million medical members at 31 December 2025, weighted to Medicare and Medicaid. |
| Pharmacy and Consumer Wellness | 139.4 billion dollars | Roughly 9,000 retail pharmacy locations plus the front store. It filled 1.8 billion prescriptions on a 30-day equivalent basis. |
An insurer, a claims processor and a retail chain. A seller who pitches "CVS Health" as one account is pitching nobody. The first qualification question is which segment holds the budget, because the buying committee, the compliance regime and the language all change with the answer.
How the buying process actually runs
There are two separate front doors, and most sellers use the wrong one. Retail merchandising submissions route through RangeMe at rangeme.com/cvs, with a published inbox for category manager questions. That is the door for shampoo and vitamins. If you sell software, data or professional services it leads nowhere: enterprise purchasing is a different organisation, and the merchandising team states plainly that requests outside its remit will not be forwarded internally.
Colleagues are not allowed to buy from you. CVS Health's published Code of Conduct instructs colleagues to follow the company's procurement process and is explicit that they must not negotiate directly or sign any contract with suppliers. Contracting sits with the Strategic Procurement department, whose stated job includes obligating suppliers to comply with regulatory and client requirements. The Code also requires a Mutual Non-Disclosure Agreement before a colleague engages a vendor, routed through a central request address. The practical consequence: an enthusiastic sponsor cannot shortcut you, and a verbal commitment in a room is not a commitment.
Protected health information changes the shape of the deal. CVS Health is a HIPAA covered entity three times over, as a pharmacy, as a PBM and as an insurer. If your product touches protected health information, and in this account most useful products do, you are signing a Business Associate Agreement and going through third party risk review that extends to your own subcontractors. Build that in as a work stream with named owners, not as paperwork at the end.
Layered regulators sit behind each segment. Aetna answers to state insurance departments and to CMS for Medicare Advantage and Part D. Caremark operates under a patchwork of state PBM laws. The retail pharmacies answer to state boards of pharmacy and to the DEA. Compliance will be in the room earlier than you expect.
Who owns what, so you know where your deal sits
You will not be selling to these people. Their remit tells you which part of the company your deal lives in, and whose priorities it must survive two or three levels down.
| Name | Title as published | What it means for a vendor |
|---|---|---|
| Tilak Mandadi | Executive Vice President, Ventures and Chief Experience and Technology Officer | Enterprise technology, digital experience and the venture arm. The nearest thing to a firm-wide technology remit. |
| Steve Nelson | Executive Vice President and President, Aetna | The insurance environment. Payer language: risk adjustment, stars, medical loss ratio. |
| Ed DeVaney | Executive Vice President and President, Caremark | The PBM. It sells to employers and health plans, so anything you build here is judged as a client-facing capability. |
| Siddharth Tenneti | Senior Vice President and Interim President, Pharmacy and Consumer Wellness | Retail and store operations. An interim title: check who holds the pen before investing a quarter. |
| Sree Chaguturu, MD | Executive Vice President and President of Health Care Delivery | Clinics and care delivery. Read the caution below first. |
J. David Joyner is President, Chief Executive Officer and, effective 1 January 2026, Chair of the Board. Brian Newman is Chief Financial Officer.
Names taken from CVS Health's own leadership page and its 2026 proxy statement, verified 11 September 2026. Senior roles change. Verify at source before using any name.
One piece of timing to know before you aim
CVS Health recorded a 5.7 billion dollar goodwill impairment against the Health Care Delivery reporting unit inside Health Services during 2025, and disclosed planned closures of certain Oak Street Health clinics in 2026. Meanwhile retail grew prescription volume, helped by Rite Aid prescription file acquisitions. A vendor pitching expansion into clinic delivery is selling into a contraction. The same pitch aimed at pharmacy throughput is selling into growth. Nothing about your product changed. The segment did.
Why you cannot sell this from the bottom
A deal that justifies the cost of selling here is measured in millions a year, and for anything touching claims, clinical or pharmacy systems it runs to tens of millions across a multi-year term. That is approved by someone in the C-suite or reporting directly into it, which sets the altitude your entry point must reach. Outbound usually aims where replies are easiest, which is precisely where the authority is not. And the obstacle here is structural: a mid-level enthusiast at CVS Health is barred by the Code of Conduct from negotiating or signing anything with you. Your champion's job is to get you to Strategic Procurement with air cover, not to buy.
The layer that matters sits below the published names
Thirteen executives appear on the leadership page. The people who sponsor a purchase are one and two levels down, and at CVS Health that layer is unusually hard to map because it triples. A platform and data organisation sits under the enterprise technology remit, a separate technology and operations bench inside Aetna, another inside Caremark, plus pharmacy operations across roughly 9,000 locations. The same functional title exists three times, under three different P and Ls and three different regulators.
That is why the buying committee here is larger than in most accounts. Expect a business sponsor, a segment technology owner, privacy, information security, compliance and Strategic Procurement, at least one of whom will hold a view driven by a regulator rather than by your product. Multithreading is not optional. A single-threaded CVS Health deal is one you will lose to a reorganisation.
The board is a published second-degree map
CVS Health's board is unusually dense with sitting health care operators, which makes the two-hop paths real rather than decorative. From the 2026 proxy statement:
- Jeffrey R. Balser, M.D., Ph.D. is the sitting President and Chief Executive Officer of Vanderbilt University Medical Center and Dean of Vanderbilt University School of Medicine. He chairs the board's Health Services and Technology Committee.
- Michael F. Mahoney is the sitting Chairman, President and Chief Executive Officer of Boston Scientific, and has been CVS Health's Lead Independent Director since March 2025.
- J. Scott Kirby is the sitting Chief Executive Officer of United Airlines Holdings. Douglas H. Shulman is the sitting Chairman and Chief Executive Officer of OneMain Holdings and the former Commissioner of the Internal Revenue Service.
- Larry M. Robbins is the Founder and Chief Executive Officer of Glenview Capital Management and lead independent director of Butterfly Network.
- Guy P. Sansone is Co-Founder, Chairman and Chief Executive Officer of H2 Health and sits on the board of Pediatrix Medical Group.
- John E. Gallina joined the board in March 2026 and is the former Executive Vice President and Chief Financial Officer of Elevance Health.
- Leslie V. Norwalk is Strategic Counsel at Epstein, Becker and Green, is the former Acting Administrator of CMS, and currently sits on the boards of Arvinas, Neurocrine Biosciences and Globus Medical.
- Fernando Aguirre, who chairs the Audit Committee, is the former Chairman, President and Chief Executive Officer of Chiquita Brands International and currently serves on the boards of Barry Callebaut and Synchrony Financial.
- Anne M. Finucane is Chair of the Board of Rubicon Carbon, a current director of Williams-Sonoma, and the former Vice Chairman of Bank of America.
- Alecia A. DeCoudreaux is a former Eli Lilly executive and C. David Brown II a partner at Nelson Mullins Riley and Scarborough and a former Caremark Rx director.
Read that as a seller, not as trivia. If anyone in your network is senior at Vanderbilt University Medical Center, Boston Scientific, United Airlines, OneMain, Glenview, Elevance, Pediatrix, Neurocrine, Globus Medical, Arvinas, Synchrony or Williams-Sonoma, there is a checkable two-hop path to a CVS Health director. Note also that Roger N. Farah, the former Executive Chair, did not stand for re-election at the 2026 annual meeting, so do not build a path through him.
The other routes in
Acquisition alumni, an enormous population here. Caremark merged in 2007, Aetna in 2018, Oak Street Health more recently, and CVS Health acquired Rite Aid prescription files in 2025. Each brought in thousands of people who kept their old networks. Someone who worked at Aetna before 2018 still knows who stayed.
Health plan and PBM customers you already have. Senior payer and pharmacy leadership is a small world and people move between plans. A champion who has watched your product handle protected health information without incident is more credible than anyone on your payroll.
Integrators already inside. Large programmes here run with partners, who can route you to the team that has the problem and often want to, because it makes their own engagement stickier.
Working out which of those paths exists is what a relationship intelligence platform is for. The larger the account, the better the odds a path exists and nobody has looked.
And then you have to ask your own side
This step kills more introductions than the external ask does. Suppose the strongest path runs through one of your own board members who knows a CVS Health director. That is close to unrepeatable. You have to get that person to prioritise it, write something credible, and spend a piece of a relationship built over years, on you. Ask twice in a quarter and you will not be asked again.
The same logic applies at every level. Asking a customer champion to introduce you to a peer at Aetna or Caremark is asking them to lend you their credibility inside a small industry where reputations travel. Ask badly or too often and you do not merely lose the introduction, you damage the relationship that made it possible. Most companies have no visibility into this, and two reps approaching the same connector in the same month is common.
Three rules for the introduction itself
Ask for the segment, not the company. "An introduction to whoever owns clinical data platforms inside Aetna" is actionable. "An introduction to CVS Health" is not, because it does not say which of three businesses you mean.
Write the paragraph your connector will forward. They will not write your pitch, and if they have to, it will not go out. The forwardable blurb is the whole craft.
A warm path starts the clock, it does not skip it. You still sign a Business Associate Agreement where protected health information is in scope, still go through third party risk and security review, and still contract through Strategic Procurement. What you gain is a real conversation with someone who has a problem and a budget, months earlier.
See the warm paths into CVS Health
Everything above describes the problem: three segments, three regulators, and a rule against colleagues contracting directly. What it does not tell you is which of your own relationships already reaches inside. That is a question about your network, not theirs, and it is the one most teams answer from memory.
Boomerang maps the warm paths your company already has into accounts like CVS Health, across your team, your customers, your board and investors, and your partners. It then drafts the ask, routes it through the right connector and tracks it to a booked meeting. Book a 15-minute walkthrough and see it run against your own target accounts.
Frequently asked questions
How do you become a supplier to CVS Health?
It depends entirely on what you sell. Retail product submissions route through RangeMe at rangeme.com/cvs, with a published merchandising inbox for category manager questions. Enterprise goods and services are a separate track owned by the Strategic Procurement department. CVS Health's Code of Conduct requires a Mutual Non-Disclosure Agreement before a colleague engages a vendor and states that colleagues must not negotiate directly or sign any contract with suppliers, so contracting always lands with procurement regardless of who championed you.
Who makes technology buying decisions at CVS Health?
Purchases originate inside a segment, not centrally. Tilak Mandadi is Executive Vice President, Ventures and Chief Experience and Technology Officer, which is the closest thing to an enterprise technology remit, but Aetna under Steve Nelson and Caremark under Ed DeVaney run their own technology and operations organisations with their own regulators and budgets. The sponsor for your deal is normally one or two levels below the published leadership page, inside whichever segment owns the problem.
Is selling to Aetna different from selling to Caremark or CVS Pharmacy?
Yes, and treating them as one account is the most common and most expensive mistake in this deal. Aetna is a regulated insurer answering to state insurance departments and CMS. Caremark is a pharmacy benefit manager that sells to employers and health plans and operates under state PBM statutes. The retail pharmacies answer to state boards of pharmacy and the DEA. The buyers, the economics and the compliance reviewers are different in each, even though all three sit inside CVS Health.
How long does an enterprise sale to CVS Health take?
Assume multiple quarters. If your product touches protected health information, and in this account most useful products do, you will sign a Business Associate Agreement and go through third party risk review that extends to your subcontractors, on top of security review and procurement. None of that is skipped because the introduction was warm. What a warm introduction changes is when the clock starts and whether anyone senior is paying attention while it runs.
Can you cold email a CVS Health executive?
You can, and the usual outcome is silence rather than rejection. A company reporting 402.1 billion dollars of revenue across an insurer, a pharmacy benefit manager and roughly 9,000 retail locations attracts every vendor in health care, and senior calendars are actively protected. These are serious operators and the obstacle is arithmetic, not indifference. The message that gets read is the one forwarded by somebody the recipient already trusts, which is why the board map and your existing payer customers are worth more than any sequence.
